PDF herunterladen
CC BY-NC-ND 4.0 · Journal of Pediatric Neurology 2022; 20(04): 252-257
DOI: 10.1055/s-0041-1731395
Original Article

Evaluation of Metabolic Effects of Nusinersen in Patients with Spinal Muscular Atrophy

Lena-Luise Becker
1   Department of Pediatric Neurology, Charité–Universitätsmedizin Berlin, Berlin, Germany
2   Center for Chronically Sick Children, Charité–Universitätsmedizin, Berlin, Germany
3   Institute for Cell Biology and Neurobiology, Charité–Universitätsmedizin Berlin, Berlin, Germany
,
Claudia Weiss
2   Center for Chronically Sick Children, Charité–Universitätsmedizin, Berlin, Germany
,
René Günther
4   Department of Neurology, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
5   Deutsches Zentrum für Neurodegenerative Erkrankungen, Dresden, Germany
,
Andreas Hermann
4   Department of Neurology, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
6   Department of Neurology, Translational Neurodegeneration Section, University Medical Center Rostock, Albrecht-Kossel, University of Rostock, Rostock, Germany
7   German Center for Neurodegenerative Diseases Rostock, Rostock, Germany
,
Manuela Theophil
8   Department of Pediatric Neurology, DRK Kliniken Berlin Westend, Berlin, Germany
,
Angela Hübner
9   Department of Pediatrics, Technische Universität Dresden, Medizinische Fakultät Carl Gustav Carus, Dresden, Germany
,
Martin Smitka
10   Department of Pediatric Neurology, Technische Universität Dresden, Medizinische Fakultät Carl Gustav Carus, Dresden, Germany
,
Maja von der Hagen
10   Department of Pediatric Neurology, Technische Universität Dresden, Medizinische Fakultät Carl Gustav Carus, Dresden, Germany
,
Angela M. Kaindl
1   Department of Pediatric Neurology, Charité–Universitätsmedizin Berlin, Berlin, Germany
2   Center for Chronically Sick Children, Charité–Universitätsmedizin, Berlin, Germany
3   Institute for Cell Biology and Neurobiology, Charité–Universitätsmedizin Berlin, Berlin, Germany
› Institutsangaben Funding The study was funded by Charité – Universitätsmedizin Berlin and the German Research Foundation (DFG, SFB1315, FOR3004).
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Nusinersen is the first disease-modifying therapy for spinal muscular atrophy (SMA), but there are few data on potential long-term endocrinological and metabolic systemic effects of this novel treatment as well as metabolic alterations in SMA itself. In this retrospective and multicentric study, we analyzed anthropometric, endocrinological, and motor function data of 81 pediatric and adult patients with SMA1 to 3 undergoing treatment with nusinersen. In 39 patients (51%), we observed a slight increase in body mass index (BMI) centiles under treatment with nusinersen, especially in patients with SMA2 and in pediatric patients between 3.1 and 12 years. A correlation to the SMN2 copy number or motor function was not found. Additionally, length centiles decreased significantly under treatment. The results of longitudinal endocrinological assessments were interpreted as not clinically significant in most patients; in three patients, the signs of an altered glucose metabolism were present. Our study indicates a putative effect of treatment with nusinersen on BMI, which might be due to a conjoint effect of weight gain and reduction of height velocity, without evidence of correlation to increased muscle function. Further studies need to address specific effects of targeted therapies such as nusinersen or onasemnogene abeparvovec on body composition including fat and muscle mass.

Keywords

spinal muscular atrophy - nusinersen - endocrinological data - anthropometric data - side effects - weight

Authors' Contributions

M.S. received compensations for presentations and training activities for Biogen. M.V.D.H. and C.W. received compensations for presentations and taking part in advisory boards from Biogen, Avexis and Sarepta. R.G. has received compensations for presentations/advisory boards from Biogen, and A.M.K. received compensations for taking part in advisory boards from Avexis and GW Pharma. A.H. has received honoraria for presentations/advisory boards from Desitin and Biogen, royalties from Elsevier Press and serves as an editorial board member of BMC neurology.


Supplementary Material



Publikationsverlauf

Eingereicht: 17. Dezember 2020

Angenommen: 02. Mai 2021

Artikel online veröffentlicht:
03. Juli 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin 2015; 33 (04) 831-846
    CrossrefPubMedGoogle Scholar
  • 2 Darras BT, Farrar MA, Mercuri E. et al. An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials. CNS Drugs 2019; 33 (09) 919-932
    CrossrefPubMedGoogle Scholar
  • 3 Hamilton G, Gillingwater TH. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med 2013; 19 (01) 40-50
    CrossrefPubMedGoogle Scholar
  • 4 Kölbel H, Hauffa BP, Wudy SA, Bouikidis A, Della Marina A, Schara U. Hyperleptinemia in children with autosomal recessive spinal muscular atrophy type I-III. PLoS One 2017; 12 (03) e0173144
    CrossrefPubMedGoogle Scholar
  • 5 Mercuri E, Darras BT, Chiriboga CA. et al; CHERISH Study Group. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 2018; 378 (07) 625-635
    CrossrefPubMedGoogle Scholar
  • 6 Bowerman M, Swoboda KJ, Michalski JP. et al. Glucose metabolism and pancreatic defects in spinal muscular atrophy. Ann Neurol 2012; 72 (02) 256-268
    CrossrefPubMedGoogle Scholar
  • 7 Bowerman M, Michalski JP, Beauvais A, Murray LM, DeRepentigny Y, Kothary R. Defects in pancreatic development and glucose metabolism in SMN-depleted mice independent of canonical spinal muscular atrophy neuromuscular pathology. Hum Mol Genet 2014; 23 (13) 3432-3444
    CrossrefPubMedGoogle Scholar
  • 8 Poruk KE, Davis RH, Smart AL. et al. Observational study of caloric and nutrient intake, bone density, and body composition in infants and children with spinal muscular atrophy type I. Neuromuscul Disord 2012; 22 (11) 966-973
    CrossrefPubMedGoogle Scholar
  • 9 Pechmann A, Langer T, Wider S, Kirschner J. Single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1. Eur J Paediatr Neurol 2018; 22 (01) 122-127
    CrossrefPubMedGoogle Scholar
  • 10 Arkblad EL, Darin N, Berg K. et al. Multiplex ligation-dependent probe amplification improves diagnostics in spinal muscular atrophy. Neuromuscul Disord 2006; 16 (12) 830-838
    CrossrefPubMedGoogle Scholar
  • 11 Finkel RS, Mercuri E, Darras BT. et al; ENDEAR Study Group. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017; 377 (18) 1723-1732
    CrossrefPubMedGoogle Scholar
  • 12 Sproule DM, Montes J, Montgomery M. et al. Increased fat mass and high incidence of overweight despite low body mass index in patients with spinal muscular atrophy. Neuromuscul Disord 2009; 19 (06) 391-396
    CrossrefPubMedGoogle Scholar
  • 13 Mannaa MM, Kalra M, Wong B, Cohen AP, Amin RS. Survival probabilities of patients with childhood spinal muscle atrophy. J Clin Neuromuscul Dis 2009; 10 (03) 85-89
    CrossrefPubMedGoogle Scholar
  • 14 Baranello G, De Amicis R, Arnoldi MT. et al. Evaluation of body composition as a potential biomarker in spinal muscular atrophy. Muscle Nerve 2020; 61 (04) 530-534
    CrossrefPubMedGoogle Scholar
  • 15 Berti B, Onesimo R, Leone D. et al. Hypoglycaemia in patients with type 1 SMA: an underdiagnosed problem?. Arch Dis Child 2020; 105 (07) 707
    CrossrefPubMedGoogle Scholar
  • 16 Mercuri E, Finkel RS, Muntoni F. et al; SMA Care Group. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord 2018; 28 (02) 103-115
    CrossrefPubMedGoogle Scholar
  • 17 Butchbach ME, Rose Jr FF, Rhoades S. et al. Effect of diet on the survival and phenotype of a mouse model for spinal muscular atrophy. Biochem Biophys Res Commun 2010; 391 (01) 835-840
    CrossrefPubMedGoogle Scholar
  • 18 Finkel RS, Mercuri E, Meyer OH. et al; SMA Care group. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord 2018; 28 (03) 197-207
    CrossrefPubMedGoogle Scholar
  • 19 Harding BN, Kariya S, Monani UR. et al. Spectrum of neuropathophysiology in spinal muscular atrophy type I. J Neuropathol Exp Neurol 2015; 74 (01) 15-24
    CrossrefPubMedGoogle Scholar
  • 20 Lipnick SL, Agniel DM, Aggarwal R. et al. Systemic nature of spinal muscular atrophy revealed by studying insurance claims. PLoS One 2019; 14 (03) e0213680
    CrossrefPubMedGoogle Scholar
  • 21 Millan EZ, Ong Z, McNally GP. Paraventricular thalamus: Gateway to feeding, appetitive motivation, and drug addiction. Prog Brain Res 2017; 235: 113-137
    CrossrefPubMedGoogle Scholar
  • 22 Bertoli S, De Amicis R, Mastella C. et al. Spinal muscular atrophy, types I and II: what are the differences in body composition and resting energy expenditure?. Clin Nutr 2017; 36 (06) 1674-1680
    CrossrefPubMedGoogle Scholar